We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mutation Found Determines Nature of Host Response to MRSA Infection

By LabMedica International staff writers
Posted on 22 Sep 2019
Image: A scanning electron micrograph (SEM) of a human neutrophil ingesting MRSA (Photo courtesy of the U.S. National Institute of Allergy and Infectious Diseases).
Image: A scanning electron micrograph (SEM) of a human neutrophil ingesting MRSA (Photo courtesy of the U.S. National Institute of Allergy and Infectious Diseases).
A recent paper described the genetic factors that determine why some individuals develop chronic methicillin-resistant Staphylococcus aureus (MRSA) infections while others develop infections that resolve relatively quickly.

The severity and duration of MRSA infection varies widely between individuals. Host factors predisposing to persistent MRSA infection are poorly understood, although genetic association studies are beginning to identify potentially influential variants.

Investigators at Duke University (Durham, NC, USA) searched for such host factors by analyzing two sets of patients who had been closely matched by age, sex, health conditions, and other risk factors for MRSA bloodstream infections. Sixty-eight patients were included in the study; half with a persistent MRSA infection and half who had been able to clear the infection from their bloodstream. Whole-exome sequencing was used to pinpoint genomic differences between the two sets of patients.

Results revealed that a mutation located in the DNA of the DNMT3A region of chromosome 2p was expressed in about 62% of the patients who cleared their MRSA infection, while it was expressed in only 9% in those who had persistent infections.

In a further series of experiments, the investigators demonstrated that DNMT3A variants could alter host response to infection through increased methylation of key regulatory genes, which resulted in reduced interleukin-10 production and in turn, allowed for a more protective immune response that cleared infection.

"The increasing prevalence of antibiotic resistant staph infections has created an urgent need to better understand who is most susceptible to these difficult-to-treat S. aureus infections and why," said senior author Dr. Vance Fowler, professor of medicine, molecular genetics, and microbiology at Duke University. "Our study identifies a particular DNMT3A mutation that contributes to an increased ability to resolve MRSA infections. The mechanism for this appears to be increased methylation of gene regulatory regions, and reduced levels of the anti-inflammatory cytokine IL-10."

The MRSA paper was published in the September 16, 2019, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.

Related Links:
Duke University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)

Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image:(L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology. (Photo courtesy of St. Jude Children\'s Research Hospital)

Genomic Profiling Predicts Relapse Risk by Subtype in Pediatric Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with more than 90% of patients surviving with modern treatments. Outcomes are worse when the disease returns, however, making... Read more

Hematology

view channel
Image: The newly certified products are the CytoCell ATM Deletion FISH Probe, CytoCell IGH Plus Breakapart FISH Probe, CytoCell IGH/FGFR3 Plus Translocation, Dual Fusion FISH Probe, and CytoCell IGH/MYEOV Plus Translocation, Dual Fusion FISH Probe. (Photo courtesy of OGT)

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Onvaro’s commercial portfolio will be anchored by the binx io platform, an FDA-cleared, CLIA-waived molecular point-of-care system with more than 1,000 installed instruments. (Photo courtesy of binx health)

New Diagnostics Company Onvaro Formed to Expand Decentralized Testing

Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more